Systemic Immune-Inflammation Index Changes Predict Outcome in Stage III Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

Huang, Taosheng; Zhang, Huanqian; Zhao, Yunzheng; Li, Yanping; Wang, Guofeng; Zhang, Yunbo; Guo, Dong; Ji, Shengjun; Sun, Zhenyou

doi:10.2217/fon-2020-1272

Cited by 7 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systemic immune-inflammation index (SII) combines three immune cell counts, neutrophils, lymphocytes, and platelets, into a simple formula and comprehensively maps the cancer-related inflammatory burden [ 13 ]. SII has shown a significant association with oncological outcomes in several malignancies [ 14 , 15 ], including urothelial cancer [ 16 , 17 ], pancreatic cancer [ 18 ], non-small lung and laryngeal cancer [ 19 , 20 ], and cholangiocarcinoma [ 21 ]. Studies investigating the prognostic value of SII in RCC patients reached controversial results.…”

Section: Introductionmentioning

confidence: 99%

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Stühler¹,

Herrmann²,

Rausch³

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the predictive and prognostic value of the systemic immune-inflammation index (SII) in patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab. Methods: This retrospective study included forty-nine mRCC patients treated with first-line ipilimumab plus nivolumab at the Department of Urology of the University of Tuebingen, Germany. SII was assessed before starting ipilimumab plus nivolumab therapy at the time of first imaging and at tumor progression. Optimal SII cut-off was stratified by ROC-analysis. Univariable and multivariable Cox regression analyses were used to evaluate the predictive and prognostic value of SII. Results: Optimal SII cut-off was 788. Twenty-nine/forty-nine patients had high SII (≥788) before initiation of ipilimumab plus nivolumab. High SII was an independent prognostic factor for worse progression-free (HR 2.70, p = 0.014) and overall survival (HR 10.53, p = 0.025). The clinical benefit rate was higher for patients with low SII if compared to high SII (80% vs. 32.1%). An increase in SII > 20% from baseline after twelve weeks of therapy was associated with progression at first imaging (p = 0.003). Conclusions: SII is both prognostic and predictive and could refine decision making in patients with unclear imaging on therapy with ipilimumab plus nivolumab.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Stühler¹,

Herrmann²,

Rausch³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Inflammation-based prognostic scores such as plateletto-lymphocyte ratio (9), lymphocyte to monocyte ratio (10), and prognostic nutritional index (11) are cost-effective and reliable prognostic tools that are widely used in patients with cancer (10,12). Many studies have shown that the systemic immuneinflammation index (SII) is a useful prognostic marker for several malignant tumors, including pancreatic (13), gallbladder (14), non-small-cell lung (15), and laryngeal cancer (16), as well as for cholangiocarcinoma (17). Studies have investigated the prognostic value of SII in patients with RCC; however, the results are inconsistent (18)(19)(20)(21)(22)(23)(24)(25).…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis

Jin¹,

Yuan²,

Yuan

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe systemic immune-inflammation index (SII) is a hematological parameter based on neutrophil, platelet, and lymphocyte counts. Studies that have investigated the prognostic value of SII in patients with renal cell carcinoma (RCC) have reported controversial results. In this study, we systematically investigated the prognostic value of SII in patients with RCC.MethodsWe systematically searched English articles in the PubMed, Embase, Web of Science, and Cochrane Library databases up to October 2021. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were used to obtain pooled results.ResultsThe meta-analysis included 10 studies that enrolled 3,180 patients. A high SII was associated with poor overall survival (HR 1.75, 95% CI 1.33–2.30, p<0.001) in patients with RCC. However, a high SII was not shown to be a significant prognostic factor for progression-free survival/disease-free survival (HR 1.22, 95% CI 0.84–1.76, p=0.293) or poor cancer-specific survival (HR 1.46, 95% CI 0.68–3.12, p=0.332) in patients with RCC. A high SII was correlated with male sex (OR 1.51, 95% CI 1.11–2.04, p=0.008), Fuhrman grade G3–G4 (OR 1.80, 95% CI 1.08–3.00, p=0.024), and poor risk based on the International Metastatic Renal Cell Carcinoma Database Consortium criteria (OR 19.12, 95% CI 9.13–40.06, p<0.001).ConclusionA high SII was independently associated with poor survival outcomes in patients with RCC. Additionally, an elevated SII indicated more aggressive disease. The SII may serve as a useful cost-effective prognostic indicator in patients with RCC.

show abstract

“…If the Δ SII was less than 43, OS and FSP were more outstanding. Also, Δ SII score was found to be an independent predictor for OS and FSP [16]. Delikgoz et al showed that optimal cut-off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02, and 817, respectively.…”

Section: Figure 1 -Roc Curve Analysis For Optimal Cut-off Value Of In...mentioning

confidence: 98%

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Smorodska

Moskalenko

Kononenko

et al. 2022

EUMJ

View full text Add to dashboard Cite

Introduction. Prediction of lung cancer recurrence is one of the most urgent problems of modern oncology. Scientists are trying to find independent predictors that will help intensify, personalize the patient's treatment, and prevent the disease relapse on time. The study aimed to find indicators of inflammation that could be independent predictors of disease recurrence in patients with surgically resected non-small cell lung cancer. Materials and methods. The study was conducted retrospectively. The study group included 104 patients with non-small cell lung cancer who received surgical treatment and adjuvant chemotherapy or chemoradiotherapy from 2014 to 2018 at the Sumy Regional Clinical Oncology Dispensary. Based on the results of the blood count tests, the inflammation indices were calculated before chemotherapy or chemoradiotherapy and one month after their completion. Systemic inflammatory response index (SIRI), systemic inflammatory index (SII), neutrophil/lymphocyte ratio (NLR), platelets/lymphocytes ratio (PLR), lymphocyte/monocyte ratio (LMR), monocyte/lymphocyte ratio (MLR) were calculated. Using ROC analysis, cut-off points were found. Cox regression was used to find independent predictors of lung cancer recurrence. Results. During the observation period, relapse of the disease was recorded in 42 (40.4%) patients. The average recurrence-free survival was 56.3 months, range of 4–84.0 months (95% CI = 46.866–65.683). Before chemo- or chemoradiation therapy, the cut-off points for NLR1, PLR1, MLR1, LMR1, SII1, and SIRI1 were 1.80, 126.35, 0.22, 4.80, 521.22 and 0.96, respectively. Cut-off points for NLR2, PLR2, MLR2, LMR2, SII2, and SIRI2 at stage one month after completing courses of chemotherapy or chemoradiotherapy were 1.33, 153.80, 0.26, 3.98, 450.10 and 0.82 respectively. According to ROC analysis, only PLR1, SII1, LMR1, and LMR2 indices are reliable and can be used in further Cox regression analysis. Univariant Cox regression showed that LMR1 and SII1 were significantly associated with disease recurrence. Multivariate Cox regression identified SII1 as the only independent predictor of disease recurrence. Conclusions. Among numerous inflammation indices as an independent predictor for disease recurrence in non-small cell lung cancer patients who received surgical treatment and chemotherapy or chemoradiotherapy, only systemic inflammation index (SII1) at the stage before chemotherapy or chemoradiotherapy can be used. Indicators above 521.22 could be a predictor of high-risk recurrence of lung cancer.

show abstract

Systemic Immune-Inflammation Index Changes Predict Outcome in Stage III Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

Cited by 7 publications

References 41 publications

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About